Title:
KIF18A INHIBITOR AND USE
Document Type and Number:
WIPO Patent Application WO/2024/022508
Kind Code:
A1
Abstract:
Provided are a heterocyclic compound as represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The compound has a relatively good KIF18A inhibition effect.
Inventors:
ZHANG XUEJUN (CN)
ZANG YANG (CN)
LI QUN (CN)
DING XIAOHUA (CN)
SUN XIAOCHUAN (CN)
FU HAOLIANG (CN)
HU WENBING (CN)
YANG YANG (CN)
ZHU HAIYONG (CN)
LI LI'E (CN)
YANG JUN (CN)
ZANG YANG (CN)
LI QUN (CN)
DING XIAOHUA (CN)
SUN XIAOCHUAN (CN)
FU HAOLIANG (CN)
HU WENBING (CN)
YANG YANG (CN)
ZHU HAIYONG (CN)
LI LI'E (CN)
YANG JUN (CN)
Application Number:
PCT/CN2023/109903
Publication Date:
February 01, 2024
Filing Date:
July 28, 2023
Export Citation:
Assignee:
WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN)
International Classes:
C07D487/04; A61K31/438; A61P35/00
Domestic Patent References:
| WO2021026098A1 | 2021-02-11 | |||
| WO2021026100A1 | 2021-02-11 | |||
| WO2021026099A1 | 2021-02-11 | |||
| WO2020132653A1 | 2020-06-25 | |||
| WO2020132651A1 | 2020-06-25 | |||
| WO2023174175A1 | 2023-09-21 | |||
| WO2023088441A1 | 2023-05-25 | |||
| WO2021211549A1 | 2021-10-21 |
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF:
Previous Patent: PHARMACEUTICAL COMPOSITION COMPRISING KRAS G12D INHIBITOR
Next Patent: METHODS FOR PROMOTING PERSISTENCE OF CELL THERAPY
Next Patent: METHODS FOR PROMOTING PERSISTENCE OF CELL THERAPY